Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Michio Kanekiyo"'
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/235d44fcb4a64fba89f8c186629bc9ac
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment
Externí odkaz:
https://doaj.org/article/37323811cfca4e539a625fdbaee2b067
Autor:
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer, Randall J. Bateman
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-17 (2022)
Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of th
Externí odkaz:
https://doaj.org/article/a6d9281674a5413f8b67e7a74816d854
Autor:
Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer, Donald A. Berry
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-9 (2022)
Abstract Background Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-month phase 2 proof-of-c
Externí odkaz:
https://doaj.org/article/4ce48fe8ab7742dd95eb4cc183c3ed7b
Autor:
Santiago Bullich, Andre Mueller, Susan De Santi, Norman Koglin, Stephen Krause, June Kaplow, Michio Kanekiyo, Núria Roé-Vellvé, Audrey Perrotin, Aleksandar Jovalekic, David Scott, Michelle Gee, Andrew Stephens, Michael Irizarry
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-13 (2022)
Abstract Background The ability of 18F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer’s disease (AD) has been demonstrated in previous studies. The objective of this work was to evaluate tau deposition using 18F-PI-26
Externí odkaz:
https://doaj.org/article/8e77b5cba44a4f58a7c6388004ac5e5a
Autor:
Lawrence S. Honig, Jerome Barakos, Shobha Dhadda, Michio Kanekiyo, Larisa Reyderman, Michael Irizarry, Lynn D. Kramer, Chad J. Swanson, Marwan Sabbagh
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 1, Pp n/a-n/a (2023)
Abstract INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid‐related imaging abnormalities (ARIA) pro
Externí odkaz:
https://doaj.org/article/3cf542a8e09a48118eb52ac3667c50a8
Autor:
Ishani Landry, Michio Kanekiyo, Jagadeesh Aluri, David JianJun Li, Ziad Hussein, Larisa Reyderman, Shobha Dhadda, Chad J Swanson, Michael C Irizarry, Lynn D Kramer
Publikováno v:
Alzheimer's & Dementia. 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::646124d8050f110613f15ede5363a995
https://doi.org/10.1002/alz.066289
https://doi.org/10.1002/alz.066289
Autor:
Joshua Grill, Doris P. Molina‐Henry, Reisa A. Sperling, Shobha Dhadda, Kate Tranotti, Russell Harris, Theresa Devins, Chad J Swanson, Michio Kanekiyo, Michelle Gee, Michael C Irizarry, Lynn D Kramer, Paul Aisen, Rema Raman
Publikováno v:
Alzheimer's & Dementia. 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30be290bd33239a4ab7d99ad06130ca0
https://doi.org/10.1002/alz.069198
https://doi.org/10.1002/alz.069198
Autor:
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael Irizarry, Lynn D. Kramer, Takeshi Iwatsubo
Publikováno v:
The New England journal of medicine. 388(1)
The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed6010659ef40d19908939303a249e6
https://pubmed.ncbi.nlm.nih.gov/36599073
https://pubmed.ncbi.nlm.nih.gov/36599073
Autor:
Donald A. Berry, Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Lynn D. Kramer, Scott M. Berry
Publikováno v:
JAMA Network Open. 6:e237230
ImportanceBayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the bayesian approach will only continue to increase. Innovations possible when using the bayesian appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a8097c03c217335fc7eea931d788acd
https://doi.org/10.1001/jamanetworkopen.2023.7230
https://doi.org/10.1001/jamanetworkopen.2023.7230